Osamu Yokosuka

33.8k total citations · 3 hit papers
668 papers, 19.0k citations indexed

About

Osamu Yokosuka is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Osamu Yokosuka has authored 668 papers receiving a total of 19.0k indexed citations (citations by other indexed papers that have themselves been cited), including 430 papers in Hepatology, 371 papers in Epidemiology and 142 papers in Surgery. Recurrent topics in Osamu Yokosuka's work include Liver Disease Diagnosis and Treatment (264 papers), Hepatitis C virus research (220 papers) and Hepatitis B Virus Studies (202 papers). Osamu Yokosuka is often cited by papers focused on Liver Disease Diagnosis and Treatment (264 papers), Hepatitis C virus research (220 papers) and Hepatitis B Virus Studies (202 papers). Osamu Yokosuka collaborates with scholars based in Japan, United States and China. Osamu Yokosuka's co-authors include Fumio Imazeki, Masao Omata, Tatsuo Kanda, Hiromitsu Saisho, Masao Ohto, Tetsuhiro Chiba, Keiichi Fujiwara, Hitoshi Maruyama, Kenichi Fukai and Toshiki Ehata and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Osamu Yokosuka

649 papers receiving 18.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan

1999 854 citations Haruhiko Yoshida, Yasushi Shiratori et al. profile →
Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

2000 573 citations Yasushi Shiratori, Fumio Imazeki et al. profile →
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties

2006 529 citations Tetsuhiro Chiba, Osamu Yokosuka et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Osamu Yokosuka Japan	63	11.6k	10.5k	3.3k	2.9k	2.9k	668	19.0k
Kwang‐Hyub Han South Korea	72	19.0k 1.6×	16.1k 1.5×	1.7k 0.5×	3.5k 1.2×	2.5k 0.9×	623	24.3k
Masahiro Kobayashi Japan	57	11.3k 1.0×	9.8k 0.9×	1.7k 0.5×	1.4k 0.5×	1.7k 0.6×	473	15.3k
Michael Torbenson United States	66	9.2k 0.8×	12.7k 1.2×	5.8k 1.8×	4.0k 1.3×	2.3k 0.8×	297	22.7k
Markus Peck‐Radosavljevic Austria	66	9.7k 0.8×	8.4k 0.8×	1.9k 0.6×	3.1k 1.1×	1.8k 0.6×	376	14.7k
Hiromitsu Kumada Japan	70	16.1k 1.4×	13.8k 1.3×	2.0k 0.6×	1.3k 0.4×	1.8k 0.6×	554	19.9k
Swan N. Thung United States	69	7.5k 0.6×	6.4k 0.6×	4.2k 1.3×	4.3k 1.5×	2.9k 1.0×	320	17.0k
Linda D. Ferrell United States	60	10.3k 0.9×	13.0k 1.2×	2.9k 0.9×	6.6k 2.2×	2.2k 0.8×	222	21.7k
Yasushi Shiratori Japan	64	6.8k 0.6×	6.4k 0.6×	2.4k 0.7×	4.8k 1.6×	2.9k 1.0×	346	15.8k
Jung‐Hwan Yoon South Korea	59	6.8k 0.6×	6.7k 0.6×	2.8k 0.8×	2.8k 0.9×	2.1k 0.7×	425	13.6k
Michio Sata Japan	58	7.1k 0.6×	6.8k 0.6×	3.1k 0.9×	2.6k 0.9×	2.1k 0.7×	457	15.1k

Countries citing papers authored by Osamu Yokosuka

Since Specialization

Citations

This map shows the geographic impact of Osamu Yokosuka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Osamu Yokosuka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Osamu Yokosuka more than expected).

Fields of papers citing papers by Osamu Yokosuka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Osamu Yokosuka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Osamu Yokosuka. The network helps show where Osamu Yokosuka may publish in the future.

Co-authorship network of co-authors of Osamu Yokosuka

This figure shows the co-authorship network connecting the top 25 collaborators of Osamu Yokosuka. A scholar is included among the top collaborators of Osamu Yokosuka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Osamu Yokosuka. Osamu Yokosuka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kanda, Tatsuo, Tian‐Cheng Li, Masaharu Takahashi, et al.. (2024). Recent advances in hepatitis E virus research and the Japanese clinical practice guidelines for hepatitis E virus infection. Hepatology Research. 54(8). 1–30. 5 indexed citations

Kanda, Tatsuo, Reina Sasaki, Koji Ishii, et al.. (2023). Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan. Hepatology Research. 54(1). 4–23. 6 indexed citations

Nishida, Nao, Masaya Sugiyama, Hiromi Sawai, et al.. (2018). Key HLA‐DRB1‐DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. Hepatology. 68(3). 848–858. 45 indexed citations

Yokosuka, Osamu, Gerold Meinhardt, & Jordi Bruix. (2017). Regorafenib as second-line treatment for patients with HCC who progressed on sorafenib: Japanese subgroup analysis of phase 3 RESORCE trial. 58. 65. 1 indexed citations

Arai, Makoto, Kenichiro Okimoto, Hideaki Ishigami, et al.. (2016). A randomized controlled trial comparing water exchange and air insufflation during colonoscopy without sedation. International Journal of Colorectal Disease. 31(6). 1217–1223. 11 indexed citations

Bruix, Jordi, Philippe Merle, Alessandro Granito, et al.. (2016). Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial. Annals of Oncology. 27. vi564–vi564. 8 indexed citations

Nakamura, Masato, Tatsuo Kanda, Shingo Nakamoto, et al.. (2013). No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV. PLoS ONE. 8(12). e81312–e81312. 30 indexed citations

Maruyama, Hitoshi, Masanori Takahashi, Tadashi Sekimoto, et al.. (2012). Heterogeneity of Microbubble Accumulation: A Novel Approach to Discriminate Between Well-Differentiated Hepatocellular Carcinomas and Regenerative Nodules. Ultrasound in Medicine & Biology. 38(3). 383–388. 9 indexed citations

Kanda, Tatsuo, Shuang Wu, Tomoko Kiyohara, et al.. (2012). Interleukin-29 Suppresses Hepatitis A and C Viral Internal Ribosomal Entry Site-Mediated Translation. Viral Immunology. 25(5). 379–386. 16 indexed citations

10.

Sogawa, Kazuyuki, Yoshio Kodera, Mamoru Satoh, et al.. (2010). Increased Serum Levels of Pigment Epithelium-Derived Factor by Excessive Alcohol Consumption-Detection and Identification by a Three-Step Serum Proteome Analysis. Alcoholism Clinical and Experimental Research. 35(2). 211–217. 19 indexed citations

11.

Hamano, Yuki, Takahiro Aoki, Ryota Shirai, et al.. (2009). Low-Dose Darbepoetin α Attenuates Progression of a Mouse Model of Aristolochic Acid Nephropathy through Early Tubular Protection. Nephron Experimental Nephrology. 114(2). e69–e81. 18 indexed citations

12.

Fujiwara, Keiichi, Hiroshige Kojima, Yutaka Yonemitsu, et al.. (2009). Phylogenetic analysis of hepatitis A virus in sera from patients with hepatitis A of various severities. Liver International. 29(6). 838–845. 14 indexed citations

13.

Chiba, Tetsuhiro, Satoru Miyagi, Atsunori Saraya, et al.. (2008). The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma. Cancer Research. 68(19). 7742–7749. 160 indexed citations

14.

Fukai, Kenichi, et al.. (2007). Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase. Journal of Viral Hepatitis. 14(9). 661–666. 10 indexed citations

15.

Muroyama, Ryosuke, Naoya Kato, Haruhiko Yoshida, et al.. (2006). Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. Journal of Hepatology. 45(6). 805–812. 56 indexed citations

16.

Kanda, Tatsuo, Osamu Yokosuka, Keiichi Nagao, & Hiromitsu Saisho. (2005). State of hepatitis C viral replication enhances activation of NF-kB- and AP-1-signaling induced by hepatitis B virus X. Cancer Letters. 234(2). 143–148. 20 indexed citations

17.

Kanda, Tatsuo, Osamu Yokosuka, Fumio Imazeki, Makoto Arai, & Hiromitsu Saisho. (2005). Enhanced Sensitivity of Human Hepatoma Cells to 5-Fluorouracil by Small Interfering RNA Targeting Bcl-2. DNA and Cell Biology. 24(12). 805–809. 16 indexed citations

18.

Yoshida, Haruhiko, Yasuyuki Arakawa, Michio Sata, et al.. (2002). Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 123(2). 483–491. 194 indexed citations

19.

Omata, Masao, Yoshimi ITO, Osamu Yokosuka, et al.. (1989). Histological changes of the liver by treatment of chronic non-A, non-B hepatitis with recombinant leukocyte interferon alpha. Digestive Diseases and Sciences. 34(3). 330–337. 62 indexed citations

20.

Tagawa, Masami, Masao Omata, Osamu Yokosuka, et al.. (1985). Early events in duck hepatitis B virus infection. Gastroenterology. 89(6). 1224–1229. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact